Clinical trial · no report yet · Phase 3
STELLAR-304
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- NCT05678673 ↗
- Active not recruiting
- Exelixis
- 60 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 22 | |
| X threads | 21 | |
| Podcasts | 15 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Clear Cell Renal Cell Carcinoma
- Interventions
- XL092; Nivolumab; Sunitinib Malate
- Arms
- XL092 + Nivolumab · Experimental
- Sunitinib Malate · Active comparator
- Enrollment
- 317
- Primary outcomes
- Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)
- Objective response rate (ORR) as assessed by BIRC per RECIST 1.1
- Sponsor
- Exelixis
- Start
- Jan 1, 2023
- Primary completion
- Dec 15, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05678673 · updated Jul 29, 2026
Publications
linked from the registry- Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Future Oncol. 2025 Mar;21(7):787-794. doi: 10.1080/14796694.2025.2458395. Epub 2025 Feb 26. PubMed 40008409